Sertoli-Leydig cell tumor
Sertoli-stromal cell tumor; Arrhenoblastoma; Androblastoma; Ovarian cancer - Sertoli-Leydig cell tumor
Sertoli-Leydig cell tumor (SLCT) is a rare cancer of the ovaries. The cancer cells produce and release a male sex hormone called testosterone.
The exact cause of this tumor is not known. Changes (mutations) in genes may play a role.
SLCT occur most often in young women 20 to 30 years old. But the tumor can occur at any age.
The Sertoli cells are normally located in the male reproductive glands (the testes). They feed sperm cells. The Leydig cells, also located in the testes, release a male sex hormone.
These cells are also found in a woman's ovaries, and in very rare cases lead to cancer. SLCT starts in the female ovaries, mostly in one ovary. The cancer cells release a male sex hormone. As a result, the woman may develop symptoms such as:
- A deep voice
- Enlarged clitoris
- Facial hair
- Loss in breast size
- Stopping of menstrual periods
Pain in the lower belly (pelvic area) is another symptom. It occurs due to the tumor pressing on nearby structures.
Exams and Tests
Early treatment results in a good outcome. Feminine characteristics usually return after surgery. But male characteristics resolve more slowly.
For more advanced stage tumors, outlook is less positive.
Crum CP, Laury AR, Hirsch MS, Quick CM, Peters WA. Sertoli-Leydig cell tumor. In: Crum CP, Laury AR, Hirsch MS, Quick CM, Peters WA, eds. Gynecologic and Obstetric Pathology. Philadelphia, PA: Elsevier; 2016:693-695.
Penick ER, Hamilton CA, Maxwell GL, Marcus CS. Germ cell, stromal, and other ovarian tumors. In: DiSaia PJ, Creasman WT, Mannel RS, McMeekin DS, Mutch DG, eds. Clinical Gynecologic Oncology. 9th ed. Philadelphia, PA: Elsevier; 2018:chap 12.
Smith RP. Sertoli-Leydig cell tumor (arrhenoblastoma). In: Smith RP, ed. Netter's Obstetrics & Gynecology. 3rd ed. Philadelphia, PA: Elsevier; 2018:chap 158.
Last reviewed on: 4/11/2018
Reviewed by: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.